Cell-free genetic testing of embryos
Volume 113, Issue 2, Pages 258–259
Lynsey Cree, Cynthia Farquhara,
The in vitro fertilization (IVF) industry is known for its enthusiasm for new technologies. The field of preimplantation genetic testing has witnessed many scientific advances in the last decade. Yet, the evidence to date about whether genetic testing of embryos to identify aneuploidy remains inconclusive despite recent larger and better studies (1). Questions continue about whether there is benefit in terms of improving live birth rates and at the same time balancing against other outcomes such as reducing miscarriage, reducing the time to pregnancy and the number of embryo transfers. There is also the trade off about assessing the clinical benefits such as livebirth and allowing development and access to innovative technologies that may be of benefit, without compromising safety and increasing the already considerable financial burden to the patient.